Contact us in Quebec


Here in Quebec, we are home to a strong community of volunteers, donors and sponsors, as well as an innovative team of researchers and health professionals. These people are the heart and soul of our organization, and there are so many exciting ways to get involved! Every volunteer, donor, researcher and sponsor helps us to improve the lives of those affected by Crohn’s disease and ulcerative colitis, and brings us closer to finding cures.

For general and in-memory donations, please call 514-342-0666 ext. 201
For French inquiries, please call 514-342-0666 ext. 202


Director, Major Gifts and Corporate Engagement, Quebec
Katherine Digby


Development and Community Engagement, Montréal
Konstantine Malakos

514-968-2079

Speaker giving a presentation

Fertility and Pregnancy in Crohn’s and Colitis

Fertility and Pregnancy in Crohn’s and ColitisDate: September 12, 2024Time: 7:00 - 8:30 p.m. ET Did you know that Crohn’s and colitis may impact the fertility of both men and women ...

 • 
ZOOM (Virtual)
 • 
Speaker giving a presentation

Ostomy Care in Crohn’s and Colitis

Ostomy Care in Crohn’s and ColitisDate: October 8, 2024Time: 7:00 - 8:30 p.m. ET Are you, or a loved one, getting ready to live with an ostomy? Have you ever wondered how to maintain a ...

 • 
ZOOM (Virtual)
 • 
Speaker giving a presentation

From Childhood to the Elderly: Navigating IBD Care

From Childhood to the Elderly: Navigating IBD CareDate: November 26, 2024Time: 7:00 - 8:30 p.m. ET Have you ever wondered how Crohn’s disease and ulcerative colitis impact different age ...

 • 
ZOOM (Virtual)
 • 
Remember to bookmark this page.

PROVINCE OF QUEBEC’S OFFICE

5530 Rue Ferrier
Mont-Royal, QC H4P 1M2

kdigby@crohnsandcolitis.ca 514-342-0666 ext. 200 1-800-461-4683 (Québec and NB only)

Search by Postal Code

News

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

 6 7 8 9 10 11 12 13 14 15